How big is the U.S. osteoarthritis injectables market?

The U.S. osteoarthritis injectables market size was estimated at USD 3.99 billion in 2023 and is expected to reach USD 4.24 billion in 2024.

What is the U.S. osteoarthritis injectables market growth?

The U.S. osteoarthritis injectables market is expected to grow at a compound annual growth rate of 6.82% from 2024 to 2030 to reach USD 6.30 billion by 2030.

Which segment accounted for the largest U.S. osteoarthritis injectables market share?

Hyaluronic Acid (HA) injections segment dominated the osteoarthritis injectables market, accounting for a share of 38.73% in 2023. This can be attributed to the high effectiveness of drugs to reduce the symptoms of osteoarthritis & their potential benefits and recent development in HA injection therapy for osteoarthritis treatment.

Who are the key players in U.S. osteoarthritis injectables market?

Market players operating in market include Anika Therapeutics, Inc., Bioventus., Ferring Pharmaceuticals Inc., Sanofi S.A., Flexion Therapeutics, Inc., and Zimmer Biomet.

What are the factors driving the U.S. osteoarthritis injectables market?

The increasing prevalence of osteoarthritis, growing risk of developing osteoarthritis in the aging population, and rising Research & Development (R&D) activities to develop novel therapies are some key factors expected to drive market growth over the forecast period.